Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

V. A. Papadimitrakopoulou, Y. L. Wu, J. Y. Han, M. J. Ahn, S. S. Ramalingam, T. John, I. Okamoto, J. C.H. Yang, K. C. Bulusu, G. Laus, B. Collins, J. C. Barrett, J. Chmielecki, T. S.K. Mok

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)viii741
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
Publication statusPublished - Oct 1 2018

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Papadimitrakopoulou, V. A., Wu, Y. L., Han, J. Y., Ahn, M. J., Ramalingam, S. S., John, T., Okamoto, I., Yang, J. C. H., Bulusu, K. C., Laus, G., Collins, B., Barrett, J. C., Chmielecki, J., & Mok, T. S. K. (2018). Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii741. https://doi.org/10.1093/annonc/mdy424.064